|
David M. Mott brings decades of leadership experience to Ambit's board of directors. Mott became MedImmune's Chief Executive officer in October 2000 after eight years of holding various executive positions, including Vice President, with responsibility for business development, strategic planning and investor relations, Executive Vice President and Chief Financial Officer, President and Chief Operating Officer and Chief Financial Officer. Mott also served as Chairman of MedImmune Ventures' investment committee. In addition to his role as Chief Executive Officer and President of MedImmune, Mott serves as Executive Vice President of AstraZeneca and a member of AstraZeneca's senior executive team. Prior to joining MedImmune, Mott was a vice president in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co., Inc. | 